Silo Pharma Announces Successful SP-26 Ketamine Implant Tests

Silo Pharma, Inc., a biopharmaceutical company in its developmental stage, has announced encouraging results from its recent tests on the SP-26 ketamine-loaded implant, designed for treating fibromyalgia and chronic pain. The company focuses on creating innovative drug formulations and delivery systems for both traditional therapies and psychedelic treatments. The tests were conducted in collaboration with Sever Pharma Solutions.

Previously, Sever Pharma Solutions initiated the processes of scaling up, extruding, and analytically testing the SP-26 ketamine hydrochloride polymer implants. The recent tests evaluated the sterilization and dissolution of the SP-26 implants, which are based on a time-released and dose-controlled formulation preferred by Silo for ongoing preclinical research. The results demonstrated a sustained drug release of over 80% across a seven-day period, indicating a consistent delivery system. Furthermore, the implants exhibited minimal variation in essential physical properties, highlighting the safety and stability of the formulation.

Eric Weisblum, CEO of Silo, expressed confidence in the interim results, stating that they suggest strong drug stability and a reliable release profile. He emphasized the importance of these factors in delivering consistent therapeutic benefits to patients. Upcoming animal studies are planned to focus on evaluating the efficacy of these dose-controlled, time-release implants as a potential treatment for fibromyalgia and chronic pain relief.

In addition to the SP-26 implant, Silo Pharma is also developing SPC-15, a novel serotonin 4 (5-HT4) receptor agonist designed for the treatment of PTSD, anxiety, and other stress-induced affective disorders. SPC-15 is being developed as an intranasal medication. If successful in clinical trials, it could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. The company is conducting preclinical studies of SPC-15 in collaboration with Columbia University, and holds an exclusive license to develop, manufacture, and commercialize SPC-15 globally.

Silo Pharma Inc. is dedicated to developing novel therapeutics aimed at addressing underserved medical conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. The company's lead program, SPC-15, targets PTSD and stress-induced anxiety disorders through an intranasal treatment. Another noteworthy program, SP-26, is a time-release ketamine-loaded implant intended for fibromyalgia and chronic pain relief.

Beyond these two programs, Silo Pharma is also advancing preclinical research on SPC-14, an intranasal compound aimed at treating Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development efforts are conducted in collaboration with universities and independent laboratories.

Silo Pharma is committed to pioneering advancements in the biopharmaceutical field by developing innovative therapies and delivery systems that address significant unmet medical needs.